Founded in 2018, Verve Therapeutics Inc is a biotech company specialising in gene-editing techniques for the treatment of coronary arteries and cardiovascular diseases.

The first two VERV.O programs target PCSK9 and ANGPTL3, two genes that have been confirmed by human genetics and pharmacology as markers for lowering blood lipids. The company completed its initial public offering on the Nasdaq in June 2021, generating $266.7 million in gross revenue.

Verve Therapeutics Inc stock has had increased awareness and popularity among investors recently. FxPro clients can buy and also sell this asset as a CFD, speculating on the price changes.

On the page above, there is an online quote chart, as well as trading conditions applicable to this security.

For effective trading on the stock market, we recommend you check the stock prices regularly. Also, follow the corporate reports and news about the company's activities that are published on major analytical portals.

One of the most important things to pay attention to is upcoming earnings releases and dividend payment dates. You can check the monthly schedule on the Dividend & Earnings Calendar on the FxPro website. If you have a Buy position open on the ex-dividend date, your trading account will be credited with the dividend net of any withholding taxes. In the case of holding a Sell position, the whole dividend will be debited from your account. If you have questions about this, our customer support team are on hand to assist.

Start Trading VERV.O CFD Stocks with FxPro Today!